Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Anti-inflammatory agents

Study results do not support use of hydroxychloroquine in hand osteoarthritis

A study published in the Annals of Internal Medicine has shown that using hydroxychloroquine has no significant effect on osteoarthritic pain.

There is anecdotal evidence that the slow-acting anti-inflammatory treatment hydroxychloroquine, used to treat rheumatoid arthritis, could also be effective in osteoarthritis. However, data on this are limited.

In the Annals of Internal Medicine (20 February 2018), researchers carried out a 12-month randomised trial involving 248 patients with hand osteoarthritis and moderate-to-severe pain who were assigned to 200–400mg hydroxychloroquine or placebo, in addition to ongoing usual care[1].

At six months, the team found that the average hand pain score over the prior two weeks was 5.66 out of 10 in the active treatment group, compared with 5.49 in the placebo group, a non-significant difference.

The results, therefore, do not provide evidence to support the use of hydroxychloroquine in hand osteoarthritis, the researchers concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204612

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.